{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:36:52Z","timestamp":1792442212685,"version":"4.5.0"},"reference-count":187,"publisher":"American Chemical Society (ACS)","issue":"7","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["K2024088"],"award-info":[{"award-number":["K2024088"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["M2022090"],"award-info":[{"award-number":["M2022090"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071221"],"award-info":[{"award-number":["82071221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82301630"],"award-info":[{"award-number":["82301630"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005145","name":"Basic Research Program of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20230180"],"award-info":[{"award-number":["BK20230180"]}],"id":[{"id":"10.13039\/501100005145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Wuxi Science and Technology Development fund","doi-asserted-by":"publisher","award":["K20251002"],"award-info":[{"award-number":["K20251002"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Traditional Chinese Medicine Development Program of Jiangsu Province","doi-asserted-by":"publisher","award":["MS2025127"],"award-info":[{"award-number":["MS2025127"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Jiangsu Provincial Medical Key Discipline","doi-asserted-by":"publisher","award":["ZDXYS202211"],"award-info":[{"award-number":["ZDXYS202211"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lung cancer continues to be the leading cause of cancer-related deaths worldwide, primarily due to persistent challenges in early detection and the limited effectiveness of precision medicine. Although low-dose computed tomography (CT) has been widely implemented for lung cancer screening and has contributed to a measurable reduction in disease-specific mortality, its diagnostic accuracy is limited by its inability to reliably distinguish benign from malignant pulmonary nodules. Furthermore, the clinical standard for metabolic imaging\u250018F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)\u2500is significantly constrained by a high incidence of false-positive findings in patients with inflammatory conditions and frequent false-negative results in tumors exhibiting low glycolytic activity. To overcome these critical limitations, highly specific PET radiotracers have been developed to target immune checkpoints, cell surface receptors, and distinct features of the tumor microenvironment. These molecularly targeted probes offer improved biological specificity, enabling more precise visualization of tumor pathophysiology and supporting applications in early diagnosis, real-time treatment monitoring, and prognostic stratification. This review summarizes recent advances in targeted PET imaging and critically evaluates the potential of integrating these approaches with multimodal imaging, liquid biopsy, and artificial intelligence (AI)-driven radiomics to enhance diagnostic accuracy and inform therapeutic decision-making. By synthesizing key developments from both preclinical studies and clinical trials, we highlight the translational significance and future directions of target-specific PET tracers. Despite existing challenges related to tracer development, regulatory approval, and methodological standardization, the integration of next-generation whole-body PET systems with advanced artificial intelligence algorithms holds considerable promise for establishing molecular-targeted PET as a cornerstone of precision oncology in lung cancer management.<\/jats:p>","DOI":"10.1021\/cbmi.5c00289","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:21:12Z","timestamp":1770981672000},"page":"1293-1314","source":"Crossref","is-referenced-by-count":2,"title":["Specific PET Imaging\nfor Precision Management of Lung\nCancer: Advances, Clinical Translation and Future Directions"],"prefix":"10.1021","volume":"4","author":[{"given":"Chongyang","family":"Chen","sequence":"first","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, China, 214063"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Pan","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, China, 214063"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9167-2077","authenticated-orcid":true,"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, China, 214063"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Xu","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, China, 214063"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8016-2277","authenticated-orcid":true,"given":"Junjie","family":"Yan","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, China, 214063"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, China, 214063"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6976-8526","authenticated-orcid":true,"given":"Min","family":"Yang","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, China, 214063"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"3","key":"2026073101224477400_cit1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN\nestimates of incidence and mortality worldwide for 36 cancers in 185\ncountries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin"},{"issue":"10299","key":"2026073101224477400_cit2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"2026073101224477400_cit3","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2024.101133","article-title":"ROS1-rearranged non-small cell lung\ncancer: Understanding biology\nand optimizing management in the era of new approvals","volume":"53","author":"Myall","year":"2024","journal-title":"Curr. Probl. Cancer"},{"issue":"12","key":"2026073101224477400_cit4","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1016\/S2468-2667(21)00157-2","article-title":"Disparities\nin stage at diagnosis for five common cancers in China:\na multicentre, hospital-based, observational study","volume":"6","author":"Zeng","year":"2021","journal-title":"Lancet Public Health"},{"issue":"5","key":"2026073101224477400_cit5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed\ntomographic screening","volume":"365","author":"National Lung Screening Trial Research Team.","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"2026073101224477400_cit6","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.240535","article-title":"Lung Nodule Management in Low-Dose CT Screening\nfor Lung Cancer: Lessons from the NELSON Trial","volume":"313","author":"Zhong","year":"2024","journal-title":"Radiology"},{"issue":"3","key":"2026073101224477400_cit7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41571-020-00432-6","article-title":"Lung cancer\nLDCT screening and mortality reduction - evidence, pitfalls and future\nperspectives","volume":"18","author":"Oudkerk","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"2026073101224477400_cit8","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1513\/AnnalsATS.201405-197BC","article-title":"Factors that influence\nphysician decision making for indeterminate pulmonary nodules","volume":"11","author":"Vachani","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"10374","key":"2026073101224477400_cit9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S0140-6736(22)01694-4","article-title":"Lung cancer\nscreening","volume":"401","author":"Adams","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"2026073101224477400_cit10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1001\/jamainternmed.2025.0505","article-title":"Projected Lifetime Cancer Risks From\nCurrent Computed Tomography Imaging","volume":"185","author":"Smith-Bindman","year":"2025","journal-title":"JAMA Intern.\nMed."},{"issue":"5","key":"2026073101224477400_cit11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.21037\/atm-22-5246","article-title":"A narrative review\nof the clinical approach to subsolid pulmonary\nnodules","volume":"11","author":"Kim","year":"2023","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"2026073101224477400_cit12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.21037\/tlcr-24-726","article-title":"Spectral dual-layer\ndetector CT-based radiomics-deep learning for predicting pathological\naggressiveness of stage I lung adenocarcinoma: discrimination of precursor\nglandular lesions and invasive adenocarcinomas","volume":"14","author":"Wang","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"issue":"1","key":"2026073101224477400_cit13","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00551-8","article-title":"Multimodal fusion of\nliquid biopsy and CT enhances differential diagnosis\nof early-stage lung adenocarcinoma","volume":"8","author":"Zhang","year":"2024","journal-title":"npj Precis.\nOncol."},{"issue":"2","key":"2026073101224477400_cit14","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.223308","article-title":"Prior CT Improves Deep\nLearning for\nMalignancy Risk Estimation of Screening-detected Pulmonary Nodules","volume":"308","author":"Venkadesh","year":"2023","journal-title":"Radiology"},{"issue":"10","key":"2026073101224477400_cit15","doi-asserted-by":"publisher","first-page":"6781","DOI":"10.1007\/s00330-023-09686-x","article-title":"Preoperative\ncontrast-enhanced CT-based radiomics nomogram for differentiating\nbenign and malignant primary retroperitoneal tumors","volume":"33","author":"Xu","year":"2023","journal-title":"Eur. Radiol."},{"issue":"5","key":"2026073101224477400_cit16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.molcel.2024.12.023","article-title":"Deciphering\nfunctional tumor-immune\ncrosstalk through highly multiplexed imaging and deep visual proteomics","volume":"85","author":"Zheng","year":"2025","journal-title":"Mol. Cell"},{"issue":"15","key":"2026073101224477400_cit17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152549","article-title":"Recent Advances\nin PET and Radioligand Therapy for\nLung Cancer: FDG and FAP","volume":"17","author":"Lee","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026073101224477400_cit18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1053\/j.semnuclmed.2025.02.013","article-title":"Advances of PET\/CT\nin Target Delineation of Lung Cancer Before Radiation Therapy","volume":"55","author":"Richlitzki","year":"2025","journal-title":"Semin. Nucl. Med."},{"issue":"1148","key":"2026073101224477400_cit19","doi-asserted-by":"publisher","first-page":"20220339","DOI":"10.1259\/bjr.20220339","article-title":"The lung cancers:\nstaging and response, CT, 18F-FDG PET\/CT, MRI, DWI: review\nand new perspectives","volume":"96","author":"Owens","year":"2023","journal-title":"Br. J. Radiol"},{"issue":"2","key":"2026073101224477400_cit20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1053\/j.semnuclmed.2025.01.002","article-title":"FDG PET\/CT\nfor Staging Lung Carcinoma: An Update","volume":"55","author":"Sathekge","year":"2025","journal-title":"Semin.\nNucl. Med."},{"issue":"4","key":"2026073101224477400_cit21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041324","article-title":"18F-FDG PET\/CT in the\nPreoperative Diagnostic and Staging of Lung Cancer\nand as a Predictor of Lymph Node Involvement","volume":"14","author":"Viohl","year":"2025","journal-title":"J. Clin. Med."},{"issue":"2","key":"2026073101224477400_cit22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1053\/j.semnuclmed.2025.02.002","article-title":"The Role of [18F]FDG PET\/CT\nin Monitoring of Therapy Response in Lung Cancer","volume":"55","author":"Ayeni","year":"2025","journal-title":"Semin. Nucl. Med."},{"issue":"10","key":"2026073101224477400_cit23","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1007\/s00259-025-07231-0","article-title":"Leveraging machine\nlearning with dynamic 18F-FDG PET\/CT: integrating metabolic and flow\nfeatures for lung cancer differential diagnosis","volume":"52","author":"Yao","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"2026073101224477400_cit24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1053\/j.semnuclmed.2025.02.006","article-title":"Impact of [18F]FDG PET\/CT\nRadiomics and Artificial Intelligence in Clinical Decision Making\nin Lung Cancer: Its Current Role","volume":"55","author":"Safarian","year":"2025","journal-title":"Semin. Nucl.\nMed."},{"issue":"12","key":"2026073101224477400_cit25","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/jama.2014.11488","article-title":"Accuracy\nof FDG-PET\nto diagnose lung cancer in areas with infectious lung disease: a meta-analysis","volume":"312","author":"Deppen","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"2026073101224477400_cit26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00259-012-2247-0","article-title":"Quantifying\ntumour heterogeneity in 18F-FDG PET\/CT imaging by texture analysis","volume":"40","author":"Chicklore","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"2026073101224477400_cit27","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/S1470-2045(24)00395-4","article-title":"Advances and\nchallenges in precision imaging","volume":"26","author":"Hricak","year":"2025","journal-title":"Lancet Oncol."},{"issue":"9","key":"2026073101224477400_cit28","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s12149-025-02090-z","article-title":"Recent advances in theranostics and oncology\nPET: emerging radionuclides and targets","volume":"39","author":"Watabe","year":"2025","journal-title":"Ann.\nNucl. Med."},{"issue":"8","key":"2026073101224477400_cit29","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1016\/j.apsb.2025.05.030","article-title":"Advances in\nimmunoPET\/SPECT\nimaging: The role of Fab and F(ab\u2019)(2) fragments in theranostics","volume":"15","author":"Huang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"2026073101224477400_cit30","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2967\/jnumed.121.262045","article-title":"First-in-Humans Evaluation\nof a PD-L1-Binding Peptide\nPET Radiotracer in Non-Small Cell Lung Cancer Patients","volume":"63","author":"Zhou","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"9","key":"2026073101224477400_cit31","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.7150\/thno.106108","article-title":"Therapeutic\npotential of FAPI RLT in oncology: A systematic review","volume":"15","author":"Ruzzeh","year":"2025","journal-title":"Theranostics"},{"issue":"8","key":"2026073101224477400_cit32","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-24-3918","article-title":"177Lu-LNC1004\nRadioligand Therapy in Patients with End-stage Metastatic\nCancers: A Single-Center, Single-Arm, Phase II Study","volume":"31","author":"Fu","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"Supplement 1","key":"2026073101224477400_cit33","doi-asserted-by":"publisher","first-page":"4S","DOI":"10.2967\/jnumed.123.266983","article-title":"Fibroblast Activation\nProtein Inhibitor Tracers and Their Preclinical, Translational, and\nClinical Status in China","volume":"65","author":"Zhao","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026073101224477400_cit34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36377-4","article-title":"Radiochemistry for positron emission tomography","volume":"14","author":"Rong","year":"2023","journal-title":"Nat. Commun."},{"issue":"11","key":"2026073101224477400_cit35","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1007\/s00259-025-07262-7","article-title":"Insights into pet-based radiogenomics\nin oncology:\nan updated systematic review","volume":"52","author":"Filippi","year":"2025","journal-title":"Eur. J. Nucl.\nMed. Mol. Imaging"},{"issue":"6","key":"2026073101224477400_cit36","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41416-025-02948-z","article-title":"Intratumoral\nand peritumoral PET\/CT-based radiomics for non-invasively and dynamically\npredicting immunotherapy response in NSCLC","volume":"132","author":"Lin","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"8","key":"2026073101224477400_cit37","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s00259-023-06174-8","article-title":"Radionuclide-based theranostics - a promising strategy for lung cancer","volume":"50","author":"Zhu","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"2026073101224477400_cit38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","article-title":"Antitumor efficacy and\npotential mechanism of FAP-targeted radioligand\ntherapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduction Targeted Ther."},{"issue":"5","key":"2026073101224477400_cit39","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.7150\/thno.99490","article-title":"LAT1-specific PET radiotracers: Development\nand clinical\nexperiences of a new class of cancer-specific radiopharmaceuticals","volume":"15","author":"Achmad","year":"2025","journal-title":"Theranostics"},{"issue":"1","key":"2026073101224477400_cit40","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03831-z","article-title":"Translation of PET radiotracers\nfor cancer imaging: recommendations from the National Cancer Imaging\nTranslational Accelerator (NCITA) consensus meeting","volume":"23","author":"McAteer","year":"2025","journal-title":"BMC Med."},{"issue":"1","key":"2026073101224477400_cit41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47512-0","article-title":"Enhancing NSCLC recurrence prediction with PET\/CT habitat\nimaging, ctDNA, and integrative radiogenomics-blood insights","volume":"15","author":"Sujit","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"2026073101224477400_cit42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s12672-025-01826-7","article-title":"The hype\naround ctDNA guiding an informed perioperative therapeutic strategy\nin early-stage non-small cell lung cancer","volume":"16","author":"Passarella","year":"2025","journal-title":"Discovery\nOncol."},{"key":"2026073101224477400_cit43","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.109339","article-title":"Integrating\nPET\/CT, radiomics and clinical data: An advanced multi-modal approach\nfor lymph node metastasis prediction in prostate cancer","volume":"184","author":"Ogulmus","year":"2025","journal-title":"Comput. Biol. Med."},{"issue":"5","key":"2026073101224477400_cit44","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3322\/caac.70024","article-title":"Personalized care for\npatients with EGFR-mutant nonsmall cell lung\ncancer: Navigating early to advanced disease management","volume":"75","author":"Borgeaud","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"2026073101224477400_cit45","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jtho.2024.12.012","article-title":"Decoding the\nClinical and Molecular\nSignatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC:\nA Brief Report","volume":"20","author":"Tavernari","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"2026073101224477400_cit46","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/ijc.29832","article-title":"Predictive efficacy\nof (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity\nin non-small cell lung cancer patients","volume":"138","author":"Dai","year":"2016","journal-title":"Int.\nJ. Cancer"},{"issue":"6","key":"2026073101224477400_cit47","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s10967-024-09486-7","article-title":"Preparation, quality control, and\nabsorbed dose estimation of 89Zr-DFO-Cetuximab for imaging\nof EGFR-expressing tumors","volume":"333","author":"Zolghadri","year":"2024","journal-title":"J. Radioanal. Nucl.\nChem."},{"issue":"1","key":"2026073101224477400_cit48","first-page":"17","article-title":"Development and\ncharacterization\nof 89Zr-labeled panitumumab for immuno-positron emission\ntomographic imaging of the epidermal growth factor receptor","volume":"12","author":"Chang","year":"2013","journal-title":"Mol. Imaging"},{"issue":"1","key":"2026073101224477400_cit49","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltae006","article-title":"Advancements in nuclear imaging using\nradiolabeled nanobody tracers to support cancer immunotherapy","volume":"4","author":"Zeven","year":"2024","journal-title":"Immunother. Adv."},{"issue":"9","key":"2026073101224477400_cit50","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41571-025-01051-9","article-title":"Evolving\nroles of MET as a therapeutic\ntarget in NSCLC and beyond","volume":"22","author":"Lee","year":"2025","journal-title":"Nat. Rev. Clin.\nOncol."},{"issue":"4","key":"2026073101224477400_cit51","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jtho.2020.11.017","article-title":"Genetic\nHeterogeneity of MET-Aberrant NSCLC\nand Its Impact on the Outcome of Immunotherapy","volume":"16","author":"Kron","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"2026073101224477400_cit52","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid Biopsy for Advanced NSCLC: A Consensus\nStatement From the International Association for the Study of Lung\nCancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"2026073101224477400_cit53","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00259-022-05995-3","article-title":"68Ga-EMP-100\nPET\/CT-a novel method for non-invasive\nassessment of c-MET expression in non-small cell lung cancer","volume":"50","author":"Unterrainer","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"2026073101224477400_cit54","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00259-021-05596-6","article-title":"68Ga-EMP-100\nPET\/CT-a novel ligand for visualizing c-MET expression in metastatic\nrenal cell carcinoma-first in-human biodistribution and imaging results","volume":"49","author":"Mittlmeier","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"2026073101224477400_cit55","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00259-025-07441-6","article-title":"ImmunoPET\nimaging of c-Met using a nanobody-based tracer [68Ga]Ga-NOTA-PFCM01\nin pancreatic ductal adenocarcinoma models and non-human primates","volume":"53","author":"Sun","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"2026073101224477400_cit56","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1021\/acs.bioconjchem.4c00019","article-title":"Development\nof an Engineered Single-Domain Antibody for Targeting MET in Non-Small\nCell Lung Cancer","volume":"35","author":"Luo","year":"2024","journal-title":"Bioconjugate Chem."},{"issue":"2","key":"2026073101224477400_cit57","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2967\/jnumed.124.268861","article-title":"Gastrin-Releasing Peptide Receptor\nImaging and Therapy in the Era of Personalized Medicine","volume":"66","author":"Morgat","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"24","key":"2026073101224477400_cit58","doi-asserted-by":"publisher","DOI":"10.3390\/cells13242128","article-title":"GRPR Drives Metastasis\nvia CRABP2 and FNDC4 Pathways in Lung Adenocarcinoma","volume":"13","author":"Kim","year":"2024","journal-title":"Cells"},{"issue":"1","key":"2026073101224477400_cit59","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40644-024-00658-y","article-title":"Advances of radiolabeled GRPR ligands for PET\/CT imaging of cancers","volume":"24","author":"Ma","year":"2024","journal-title":"Cancer Imaging"},{"issue":"12","key":"2026073101224477400_cit60","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.2967\/jnumed.119.238808","article-title":"MITIGATE-NeoBOMB1, a Phase I\/IIa Study to Evaluate\nSafety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in\nGIST Patients","volume":"61","author":"Gruber","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"6","key":"2026073101224477400_cit61","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2967\/jnumed.123.267017","article-title":"Prospective Comparison\nof 68Ga-NeoB and 68Ga-PSMA-R2 PET\/MRI in Patients\nwith Biochemically Recurrent Prostate Cancer","volume":"65","author":"Duan","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026073101224477400_cit62","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00599-6","article-title":"Assessment of TROP2,\nCEACAM5 and DLL3 in metastatic\nprostate cancer: Expression landscape and molecular correlates","volume":"8","author":"Ajkunic","year":"2024","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"2026073101224477400_cit63","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","article-title":"Expression\nand clinical\nsignificance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung\nCancer (SCLC)","volume":"7","author":"Carvajal-Hausdorf","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"2026073101224477400_cit64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186388","article-title":"A whole-body\nimaging technique for tumor-specific diagnostics and screening of\nB7H3-targeted therapies","volume":"135","author":"Xia","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"14","key":"2026073101224477400_cit65","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1158\/0008-5472.CAN-17-0299","article-title":"Noninvasive Interrogation of DLL3 Expression in Metastatic\nSmall Cell Lung Cancer","volume":"77","author":"Sharma","year":"2017","journal-title":"Cancer Res."},{"issue":"8","key":"2026073101224477400_cit66","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1470-2045(24)00249-3","article-title":"Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade\nneuroendocrine tumours of the lung and prostate: a phase 1\/2, first-in-human\ntrial","volume":"25","author":"Tendler","year":"2024","journal-title":"Lancet Oncol."},{"issue":"1","key":"2026073101224477400_cit67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI185408","article-title":"68Ga-MY6349\nPET\/CT imaging to assess Trop2 expression in multiple types of cancer","volume":"135","author":"Chen","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"7","key":"2026073101224477400_cit68","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41571-025-01021-1","article-title":"Tumour and\nmicroenvironment crosstalk in NSCLC progression and response to therapy","volume":"22","author":"Rahal","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"2026073101224477400_cit69","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment:\nFrom cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"issue":"2","key":"2026073101224477400_cit70","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007659","article-title":"First exploration of the on-treatment changes in tumor and organ\nuptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy\nin patients with non-small cell lung cancer using whole body PET","volume":"12","author":"Pouw","year":"2024","journal-title":"J. Immunother Cancer"},{"issue":"4","key":"2026073101224477400_cit71","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s12149-024-02009-0","article-title":"Radiolabelled\nanti-PD-L1 peptide PET\/CT in predicting the efficacy of neoadjuvant\nimmunotherapy combined with chemotherapy in resectable non-small cell\nlung cancer","volume":"39","author":"Zhou","year":"2025","journal-title":"Ann. Nucl. Med."},{"issue":"4","key":"2026073101224477400_cit72","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2967\/jnumed.119.229781","article-title":"First-in-Humans Imaging with 89Zr-Df-IAB22M2C\nAnti-CD8 minibody in Patients with Solid Malignancies: Preliminary\nPharmacokinetics, Biodistribution, and Lesion Targeting","volume":"61","author":"Pandit-Taskar","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"13","key":"2026073101224477400_cit73","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1007\/s00259-022-05903-9","article-title":"Pilot study of a novel\nnanobody 68Ga-NODAGA-SNA006\nfor instant PET imaging of CD8+ T cells","volume":"49","author":"Wang","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"2026073101224477400_cit74","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1007\/s00259-024-06999-x","article-title":"Human\ndose-escalation study of PET imaging CD8+ T-cell infiltration\nin solid malignancies with [68Ga]Ga-NODAGA-SNA006","volume":"52","author":"Wang","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol.\nImaging"},{"issue":"9","key":"2026073101224477400_cit75","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","article-title":"Stromal cells in the tumor microenvironment: accomplices of tumor\nprogression?","volume":"14","author":"Zhao","year":"2023","journal-title":"Cell Death Dis"},{"issue":"2","key":"2026073101224477400_cit76","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222785","article-title":"FAPI Compared with\nFDG PET\/CT for Diagnosis of Primary and Metastatic Lung Cancer","volume":"308","author":"Wei","year":"2023","journal-title":"Radiology"},{"issue":"1","key":"2026073101224477400_cit77","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1148\/radiol.211424","article-title":"Comparison of 68Ga-FAPI and 18F-FDG PET\/CT\nin the Evaluation of Advanced Lung Cancer","volume":"303","author":"Wang","year":"2022","journal-title":"Radiology"},{"issue":"7","key":"2026073101224477400_cit78","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071437","article-title":"Clinical [18F]FSPG Positron Emission Tomography\nImaging Reveals Heterogeneity in Tumor-Associated System xc\u2013 Activity","volume":"16","author":"Sharkey","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026073101224477400_cit79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265427","article-title":"18F-FSPG\nPET imaging for the evaluation of indeterminate pulmonary nodules","volume":"17","author":"Paez","year":"2022","journal-title":"PLoS One"},{"issue":"6","key":"2026073101224477400_cit80","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2967\/jnumed.116.180422","article-title":"Pharmacokinetic\nAnalysis of Dynamic 18F-Fluoromisonidazole PET Data in\nNon-Small Cell Lung Cancer","volume":"58","author":"Schwartz","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"16","key":"2026073101224477400_cit81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164101","article-title":"First Comparison between [18F]-FMISO and [18F]-Faza for Preoperative Pet Imaging of\nHypoxia in Lung Cancer","volume":"13","author":"Thureau","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026073101224477400_cit82","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5615","article-title":"The emerging roles of CEACAM6 in\nhuman cancer (Review)","volume":"64","author":"Wu","year":"2024","journal-title":"Int. J. Oncol."},{"key":"2026073101224477400_cit83","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101402","article-title":"Overexpression of\nCEACAM6 activates Src-FAK signaling and inhibits anoikis, through\nhomophilic interactions in lung adenocarcinomas","volume":"20","author":"Kim","year":"2022","journal-title":"Transl. Oncol."},{"issue":"1","key":"2026073101224477400_cit84","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00910-z","article-title":"Cytokine\nand epigenetic regulation of CEACAM6 mediates EGFR-driven signaling\nand drug response in lung adenocarcinoma","volume":"9","author":"Zheng","year":"2025","journal-title":"npj\nPrecis. Oncol."},{"issue":"21","key":"2026073101224477400_cit85","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202415689","article-title":"A Novel Theranostic Strategy for\nMalignant Pulmonary Nodules by Targeted CECAM6 with 89Zr\/131I-Labeled Tinurilimab","volume":"12","author":"Chen","year":"2025","journal-title":"Adv. Sci."},{"issue":"7","key":"2026073101224477400_cit86","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1007\/s00259-025-07107-3","article-title":"Development and biological\nevaluation of a novel CEACAM6-targeted PET tracer for distinguishing\nmalignant nodules in early-stage lung adenocarcinoma","volume":"52","author":"Zhu","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"2026073101224477400_cit87","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2967\/jnumed.112.113563","article-title":"First experience of\n18F-alfatide in lung cancer patients using a\nnew lyophilized kit for rapid radiofluorination","volume":"54","author":"Wan","year":"2013","journal-title":"J. Nucl. Med."},{"issue":"13","key":"2026073101224477400_cit88","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00259-015-3118-2","article-title":"18F-Alfatide\nII PET\/CT in healthy human volunteers and patients with brain metastases","volume":"42","author":"Yu","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"2026073101224477400_cit89","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1021\/acs.molpharmaceut.4c01293","article-title":"Development\nof Novel Peptide-Based Radiotracers for Detecting FGL1 Expression\nin Tumors","volume":"22","author":"Xu","year":"2025","journal-title":"Mol. Pharmaceutics"},{"issue":"10","key":"2026073101224477400_cit90","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1001\/jama.2021.0377","article-title":"Screening for Lung Cancer With Low-Dose Computed\nTomography: Updated Evidence Report and Systematic Review for the\nUS Preventive Services Task Force","volume":"325","author":"Jonas","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"2026073101224477400_cit91","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(25)00082-8","article-title":"Low-dose CT for lung\ncancer screening in a high-risk population (SUMMIT): a prospective,\nlongitudinal cohort study","volume":"26","author":"Bhamani","year":"2025","journal-title":"Lancet Oncol."},{"issue":"5","key":"2026073101224477400_cit92","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.21037\/qims-21-912","article-title":"Development and validation\nof qualitative and quantitative models to predict invasiveness of\nlung adenocarcinomas manifesting as pure ground-glass nodules based\non low-dose computed tomography during lung cancer screening","volume":"12","author":"Liu","year":"2022","journal-title":"Quant. Imaging Med. Surg."},{"issue":"3","key":"2026073101224477400_cit93","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1007\/s00330-023-10130-3","article-title":"Head to head comparison\nof 68Ga-DOTA-FAPI-04 vs 18F-FDG PET\/CT in the\nevaluation of primary extrapulmonary tumors in\nthe chest","volume":"34","author":"Zhang","year":"2024","journal-title":"Eur. Radiol."},{"issue":"2","key":"2026073101224477400_cit94","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1053\/j.semnuclmed.2025.02.011","article-title":"FAPI PET in\nthe Management of Lung\nTumors","volume":"55","author":"Deleu","year":"2025","journal-title":"Semin. Nucl. Med."},{"issue":"2","key":"2026073101224477400_cit95","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00330-023-10013-7","article-title":"Performance of [18F]FDG PET\/CT versus FAPI PET\/CT for\nlung cancer assessment: a systematic review and meta-analysis","volume":"34","author":"Yang","year":"2024","journal-title":"Eur. Radiol"},{"issue":"Supplement 2","key":"2026073101224477400_cit96","first-page":"2595","article-title":"Evaluation\nof 18F-FSPG versus 18F-FDG PET imaging in\ndetecting malignancy of solitary pulmonary nodules","volume":"63","author":"Vermesh","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"431","key":"2026073101224477400_cit97","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan8840","article-title":"A PET imaging approach for determining EGFR mutation status for improved\nlung cancer patient management","volume":"10","author":"Sun","year":"2018","journal-title":"Sci. Transl.\nMed."},{"issue":"5","key":"2026073101224477400_cit98","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00259-023-06547-z","article-title":"CXCR4-directed PET\/CT\nwith [68Ga]Ga-pentixafor in solid tumors-a comprehensive\nanalysis of imaging findings and comparison with histopathology","volume":"51","author":"Dreher","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"2026073101224477400_cit99","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s00259-022-06059-2","article-title":"[68Ga]Ga-Pentixafor PET\/CT imaging for in\nvivo CXCR4 receptor mapping\nin different lung cancer histologic sub-types: correlation with quantitative\nreceptors\u2019 density by immunochemistry techniques","volume":"50","author":"Watts","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"2026073101224477400_cit100","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34627-5","article-title":"A fluorogenic\nprobe for predicting treatment\nresponse in non-small cell lung cancer with EGFR-activating mutations","volume":"13","author":"Deng","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"2026073101224477400_cit101","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01366-y","article-title":"Molecular and functional\nimaging in cancer-targeted therapy: current applications and future\ndirections","volume":"8","author":"Bai","year":"2023","journal-title":"Signal Transduction Targeted Ther."},{"issue":"2","key":"2026073101224477400_cit102","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1158\/1078-0432.CCR-21-1566","article-title":"FDA\nApproval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic\nNSCLC Harboring MET Exon 14 Skipping Mutations or Alterations","volume":"28","author":"Mathieu","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"2026073101224477400_cit103","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s00259-017-3672-x","article-title":"89Zr-Onartuzumab PET imaging of c-MET receptor\ndynamics","volume":"44","author":"Pool","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"Supplement 1","key":"2026073101224477400_cit104","first-page":"346","article-title":"Preliminary\ndiagnostic performance of [68Ga]-NeoBOMB1 in patients with\ngastrin-releasing peptide receptor-positive\nbreast, prostate, colorectal or lung tumors (NeoFIND)","volume":"61","author":"Djaileb","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"12","key":"2026073101224477400_cit105","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab\nimaging as a non-invasive approach to\nassess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat. Med."},{"issue":"5","key":"2026073101224477400_cit106","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2967\/jnumed.121.262473","article-title":"PD-L1 PET\/CT Imaging\nwith Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small\nCell Lung Cancer","volume":"63","author":"Smit","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"13","key":"2026073101224477400_cit107","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1007\/s00259-023-06373-3","article-title":"Preclinical evaluation and pilot clinical study\nof [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody\nradiotracer for\nrapid one-step radiolabeling and PET imaging","volume":"50","author":"Ma","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"2026073101224477400_cit108","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1053\/j.semnuclmed.2024.09.008","article-title":"Current and\nFuture Perspectives of PDL1 PET and SPECT Imaging","volume":"54","author":"Dev","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"2026073101224477400_cit109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108222","article-title":"Development and First-in-Human\nevaluation of a Site-Specific [18F]-Labeled PD-L1 nanobody\nPET radiotracer for noninvasive imaging in NSCLC","volume":"156","author":"Ma","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"5","key":"2026073101224477400_cit110","doi-asserted-by":"publisher","first-page":"720","DOI":"10.2967\/jnumed.121.262485","article-title":"CD8-Targeted PET Imaging\nof Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans\nStudy of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 minibody","volume":"63","author":"Farwell","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"8","key":"2026073101224477400_cit111","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.7150\/thno.79976","article-title":"In vivo imaging of CD8+ T cells in metastatic cancer patients:\nfirst clinical experience\nwith simultaneous [89Zr]Zr-Df-IAB22M2C PET\/MRI","volume":"13","author":"Schwenck","year":"2023","journal-title":"Theranostics"},{"issue":"20","key":"2026073101224477400_cit112","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.1182\/bloodadvances.2025016505","article-title":"T-cell dysregulation\ninforms radiotherapy-immunotherapy response in B-cell lymphoma: results\nfrom a phase 1 trial","volume":"9","author":"Hawkes","year":"2025","journal-title":"Blood Adv."},{"issue":"5","key":"2026073101224477400_cit113","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.ijrobp.2023.12.047","article-title":"A Novel Translational\nPET Imaging Approach to Quantifying Distal Tumor Immune Activation\nAfter Targeted Radiation Therapy and Checkpoint Blockade","volume":"118","author":"Zhang","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2026073101224477400_cit114","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07419-w","article-title":"The application\nand\nprospect of granzyme B-targeted PET imaging in cancer immunotherapy","volume":"24","author":"Tong","year":"2026","journal-title":"J. Transl. Med."},{"issue":"23","key":"2026073101224477400_cit115","doi-asserted-by":"publisher","first-page":"5252","DOI":"10.1158\/1078-0432.CCR-24-1427","article-title":"Facts and Hopes\nfor PET Imaging-Derived\nImmunotherapy Biomarkers","volume":"30","author":"de Groot","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"2026073101224477400_cit116","doi-asserted-by":"publisher","DOI":"10.3390\/ph18040459","article-title":"Hypoxia\nImaging in Lung Cancer: A PET-Based Narrative Review for Clinicians\nand Researchers","volume":"18","author":"Alenezi","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"2026073101224477400_cit117","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13014-018-1147-2","article-title":"FDG and\nFMISO PET-guided dose escalation with intensity-modulated radiotherapy\nin lung cancer","volume":"13","author":"Thureau","year":"2018","journal-title":"Radiat. Oncol."},{"issue":"5","key":"2026073101224477400_cit118","doi-asserted-by":"publisher","first-page":"628","DOI":"10.2967\/jnumed.120.247742","article-title":"18F-FLT PET\/CT Adds Value to 18F-FDG PET\/CT for Diagnosing\nRelapse After Definitive Radiotherapy in Patients with Lung Cancer:\nResults of a Prospective Clinical Trial","volume":"62","author":"Christensen","year":"2021","journal-title":"J.\nNucl. Med."},{"issue":"2","key":"2026073101224477400_cit119","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2967\/jnumed.115.166462","article-title":"PET Imaging of VEGFR-2 Expression\nin Lung Cancer with 64Cu-Labeled Ramucirumab","volume":"57","author":"Luo","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"2","key":"2026073101224477400_cit120","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6800","article-title":"RGD peptide\nin cancer targeting: Benefits, challenges, solutions, and possible\nintegrin-RGD interactions","volume":"13","author":"Javid","year":"2024","journal-title":"Cancer Med."},{"issue":"4","key":"2026073101224477400_cit121","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ird3.46","article-title":"Clinical applications\nof fibroblast activation protein-targeted theranostics in oncologic\nand nononcologic disease: Current status and future directions","volume":"1","author":"Fu","year":"2023","journal-title":"iRadiology"},{"key":"2026073101224477400_cit122","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/RLU.0000000000006210","article-title":"Exploratory\nAnalysis of [68Ga]Ga-FAP-2286 PET\/CT Quantitative\nParameters for Predicting Response to [177Lu]Lu-FAP-2286\nTherapy in Non-small Cell Lung Cancer","volume":"51","author":"Fan","year":"2026","journal-title":"Clin.\nNucl. Med."},{"issue":"12","key":"2026073101224477400_cit123","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.7150\/thno.113070","article-title":"Comparative\nstudy of [18F]AlF-NOTA-FAPI-RGD and [18F]FDG\/[18F]AlF-NOTA-FAPI-04 PET\/CT in renal cell\ncarcinoma","volume":"15","author":"Gao","year":"2025","journal-title":"Theranostics"},{"issue":"1","key":"2026073101224477400_cit124","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54852-4","article-title":"Imaging NRF2 activation\nin non-small cell lung cancer with positron emission tomography","volume":"15","author":"Greenwood","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"2026073101224477400_cit125","doi-asserted-by":"publisher","DOI":"10.1038\/s44303-024-00038-y","article-title":"[18F]FSPG-PET provides an early marker of radiotherapy response in head\nand neck squamous cell cancer","volume":"2","author":"Sambasivan","year":"2024","journal-title":"npj Imaging"},{"issue":"1","key":"2026073101224477400_cit126","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40658-024-00685-5","article-title":"PET radiomics\nin lung cancer: advances and translational challenges","volume":"11","author":"Zhang","year":"2024","journal-title":"EJNMMI Phys."},{"issue":"1","key":"2026073101224477400_cit127","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-02101-3","article-title":"Research progress\nin computer-aided diagnosis systems for lung cancer","volume":"8","author":"Ma","year":"2025","journal-title":"npj Digital Med."},{"issue":"9","key":"2026073101224477400_cit128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100688","article-title":"Effect of FDG PET-CT for Staging and Radiotherapy Planning\n- A Comparison of Cohorts From Two Randomized Trials of Thoracic Radiotherapy\nin Limited-Stage SCLC","volume":"5","author":"Graabak","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"2026073101224477400_cit129","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.945602","article-title":"Positron emission tomography\nimaging of lung cancer: An overview of alternative positron emission\ntomography tracers beyond F18 fluorodeoxyglucose","volume":"9","author":"Zhu","year":"2022","journal-title":"Front Med."},{"issue":"4","key":"2026073101224477400_cit130","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2967\/jnumed.124.268258","article-title":"Comparison\nof [68Ga]Ga-Fibroblast Activation Protein Inhibitor-04\nand [18F]FDG PET Imaging for Solitary Fibrous Tumor and\nPreliminary Application of FAP-Targeted Radiopharmaceutical Therapy","volume":"66","author":"Wang","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"12","key":"2026073101224477400_cit131","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1002\/cncr.26630","article-title":"3\u2032-deoxy-3\u2032-[18F]fluorothymidine positron emission tomography for response\nassessment in soft tissue sarcoma: a pilot study to correlate imaging\nfindings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic\nresponse","volume":"118","author":"Benz","year":"2012","journal-title":"Cancer"},{"key":"2026073101224477400_cit132","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctro.2022.06.004","article-title":"Hypoxia in\nrelationship to tumor volume using hypoxia PET-imaging in head &\nneck cancer - A scoping review","volume":"36","author":"Hildingsson","year":"2022","journal-title":"Clin. Transl.\nRadiat. Oncol."},{"issue":"12","key":"2026073101224477400_cit133","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2967\/jnumed.109.066639","article-title":"A comparison of 68Ga-DOTATATE and 18F-FDG PET\/CT in pulmonary neuroendocrine\ntumors","volume":"50","author":"Kayani","year":"2009","journal-title":"J. Nucl. Med."},{"issue":"5","key":"2026073101224477400_cit134","doi-asserted-by":"publisher","first-page":"708","DOI":"10.2967\/jnumed.115.163865","article-title":"Safety and Efficacy\nof 68Ga-DOTATATE PET\/CT for Diagnosis, Staging, and Treatment\nManagement of Neuroendocrine Tumors","volume":"57","author":"Deppen","year":"2016","journal-title":"J. Nucl.\nMed."},{"key":"2026073101224477400_cit135","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.900450","article-title":"Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients\n- an overview","volume":"12","author":"Van De Stadt","year":"2022","journal-title":"Front. Oncol."},{"issue":"8","key":"2026073101224477400_cit136","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1182\/blood.2024027727","article-title":"Combined\nPET and ctDNA response as a predictor of POD24 for follicular lymphoma\nafter first-line induction treatment","volume":"146","author":"Claudel","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026073101224477400_cit137","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15030247","article-title":"Circulating Tumor DNA\nand [18F]FDG-PET for Early Response Assessment in Patients\nwith Advanced NSCLC","volume":"15","author":"Ryssel","year":"2025","journal-title":"Diagnostics (Basel)"},{"issue":"11","key":"2026073101224477400_cit138","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jtho.2024.07.002","article-title":"Clinical Utility of\nTumor-Naive Presurgical Circulating Tumor DNA Detection in Early-Stage\nNSCLC","volume":"19","author":"Hong","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"2026073101224477400_cit139","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01174-3","article-title":"The prognostic\nand clinical utility of circulating tumor DNA in diffuse large B-cell\nlymphoma: a systematic review and meta-analysis","volume":"9","author":"Forghani","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"2","key":"2026073101224477400_cit140","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1078-0432.CCR-23-1469","article-title":"Elucidating\nthe Heterogeneity of Immunotherapy Response and Immune-Related Toxicities\nby Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung\nCancer","volume":"30","author":"Murray","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"2026073101224477400_cit141","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and\ntherapy of non-small cell lung\ncancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduction Targeted Ther."},{"issue":"9","key":"2026073101224477400_cit142","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.722","article-title":"Radiogenomics:\nbridging the gap between imaging and genomics for\nprecision oncology","volume":"5","author":"He","year":"2024","journal-title":"MedComm"},{"issue":"1","key":"2026073101224477400_cit143","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03321-5","article-title":"Oncogene-driven\nlung\ncancer in the era of radiogenomics: current evidence and future developments","volume":"16","author":"Ryan","year":"2025","journal-title":"Discovery Oncol."},{"key":"2026073101224477400_cit144","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1242392","article-title":"New research progress\non 18F-FDG\nPET\/CT radiomics for EGFR mutation prediction in lung adenocarcinoma:\na review","volume":"13","author":"Ge","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"2026073101224477400_cit145","doi-asserted-by":"publisher","DOI":"10.1038\/s44303-024-00053-z","article-title":"Clinical applications of fibroblast\nactivation protein\ninhibitor positron emission tomography (FAPI-PET)","volume":"2","author":"Mori","year":"2024","journal-title":"npj Imaging"},{"key":"2026073101224477400_cit146","unstructured":"Hasanabadi, S.; Cheraghi, M.; mansh, H.; Bayat, M.; Bakhshayesh Karam, M.; Corsi, A.; Salimi, Y.; Azimi, M. S.; Doroudinia, A.; Karami, A.; et al.; Per-Lesion Radiomics Analysis\nof [68Ga]-DOTA FAPI-46 and [18F]-FDG PET\/CT\nin Non-Small Cell Lung Cancer: A Pilot Study, 2025.10.13140\/RG.2.2.33900.63363."},{"issue":"6","key":"2026073101224477400_cit147","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s00432-025-06232-8","article-title":"A prognostic PET radiomic model for\nrisk stratification in non-small cell lung cancer: integrating radiogenomics\nand clinical features to predict survival and uncover tumor biology\ninsights","volume":"151","author":"Taheri","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol"},{"key":"2026073101224477400_cit148","doi-asserted-by":"publisher","first-page":"630","DOI":"10.2967\/jnumed.123.266749","article-title":"PET\/CT-Based Radiogenomics\nSupports KEAP1\/NFE2L2 Pathway\nTargeting for Non-Small Cell Lung Cancer Treated with Curative Radiotherapy","volume":"65","author":"Bourbonne","year":"2024","journal-title":"J. Nucl. Med."},{"key":"2026073101224477400_cit149","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-025-07453-2","article-title":"Predicting PD-L1 expression\nstatus in NSCLC using radiomic analysis of 18F-FDG-PET\/CT\nimages","volume":"53","author":"Kiss","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"2026073101224477400_cit150","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1002\/mp.17862","article-title":"Thorax-encompassing\nmulti-modality PET\/CT deep learning model for resected lung cancer\nprognostication: A retrospective, multicenter study","volume":"52","author":"Christie","year":"2025","journal-title":"Med. Phys."},{"issue":"6","key":"2026073101224477400_cit151","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1053\/j.semnuclmed.2022.05.002","article-title":"New PET\nTracers: Current Knowledge and Perspectives in Lung Cancer","volume":"52","author":"Krarup","year":"2022","journal-title":"Semin. Nucl. Med."},{"issue":"6","key":"2026073101224477400_cit152","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3322\/caac.21785","article-title":"Clinical insights into\nsmall cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and\nfuture directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"2026073101224477400_cit153","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01148-5","article-title":"Targeting tumoral heterogeneity\nin lung cancer: a novel, CT-texture-guided targeted biopsy approach\nwith exome sequencing","volume":"9","author":"Hertel","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"3","key":"2026073101224477400_cit154","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ijrobp.2023.05.019","article-title":"PD-L1\nPositron Emission\nTomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary\nResults of the ImmunoPET Phase 0 Study","volume":"117","author":"Hegi-Johnson","year":"2023","journal-title":"Int.\nJ. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"2026073101224477400_cit155","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007535","article-title":"Non-invasive\nPD-L1 quantification using [18F]DK222-PET imaging in cancer\nimmunotherapy","volume":"11","author":"Mishra","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"2026073101224477400_cit156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1272570","article-title":"A novel [89Zr]-anti-PD-1-PET-CT to assess response to\nPD-1\/PD-L1 blockade in lung cancer","volume":"14","author":"Puyalto","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"2026073101224477400_cit157","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.21037\/tlcr-24-576","article-title":"Radiomicsmetabolic signature profiles for advanced\nnon-small cell lung cancer with chemoimmunotherapy by reflecting biological\nfunction and survival","volume":"13","author":"Jiang","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"2026073101224477400_cit158","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1708692","article-title":"Radiomics\nreveals the biological basis for non-small\ncell lung cancer prognostic stratification by reflecting tumor immune\nmicroenvironment heterogeneity","volume":"16","author":"Huang","year":"2025","journal-title":"Front. Immunol."},{"issue":"Supplement 1","key":"2026073101224477400_cit159","doi-asserted-by":"publisher","first-page":"46S","DOI":"10.2967\/jnumed.123.266978","article-title":"The Role of Total-Body PET in Drug\nDevelopment and\nEvaluation: Status and Outlook","volume":"65","author":"Meng","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"4","key":"2026073101224477400_cit160","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/cpt.2548","article-title":"PET as a Translational\nTool in Drug Development for Neuroscience Compounds","volume":"111","author":"Varrone","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"2026073101224477400_cit161","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals\nand their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduction\nTargeted Ther."},{"issue":"1","key":"2026073101224477400_cit162","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-024-00258-y","article-title":"Good practices for 89Zr radiopharmaceutical production\nand quality control","volume":"9","author":"Wuensche","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"4","key":"2026073101224477400_cit163","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2967\/jnumed.119.239558","article-title":"The Role\nof 89Zr-Immuno-PET in Navigating and Derisking the Development\nof Biopharmaceuticals","volume":"62","author":"van Dongen","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"9","key":"2026073101224477400_cit164","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.2967\/jnumed.125.270011","article-title":"Proceedings: PET Drugs-A 2023 Workshop\non Product Quality, Regulatory Submissions, Facility Inspections,\nand Benefit-Risk Considerations","volume":"66","author":"Bunning","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026073101224477400_cit165","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-023-00230-2","article-title":"Position\npaper to facilitate patient access to radiopharmaceuticals: considerations\nfor a suitable pharmaceutical regulatory framework","volume":"9","author":"Korde","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"2026073101224477400_cit166","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1658588","article-title":"Pathways and\nchallenges in the clinical translational of radiopharmaceuticals for\npediatric investigations","volume":"12","author":"Stauff","year":"2025","journal-title":"Front. Med."},{"issue":"10","key":"2026073101224477400_cit167","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s11886-022-01749-7","article-title":"Regulatory Agencies and PET\/CT Imaging\nin the Clinic","volume":"24","author":"Herscovitch","year":"2022","journal-title":"Curr. Cardiol. Rep."},{"issue":"9","key":"2026073101224477400_cit168","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1021\/cbmi.4c00030","article-title":"Peptide PET Imaging: A Review of\nRecent Developments and a Look at the Future of Radiometal-Labeled\nPeptides in Medicine","volume":"2","author":"Shabsigh","year":"2024","journal-title":"Chem. Biomed. Imaging"},{"key":"2026073101224477400_cit169","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.916693","article-title":"ImmunoPET:\nAntibody-Based PET Imaging in Solid Tumors","volume":"9","author":"Manafi-Farid","year":"2022","journal-title":"Front Med."},{"issue":"10","key":"2026073101224477400_cit170","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1007\/s00259-025-07205-2","article-title":"Optimizing antibody\nPET imaging: a comparative preclinical analysis of nanobody and minibody-like\nPET tracers","volume":"52","author":"Zeven","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"2026073101224477400_cit171","doi-asserted-by":"publisher","DOI":"10.3390\/biom11050637","article-title":"Nanobodies for Medical Imaging: About\nReady for Prime\nTime?","volume":"11","author":"Berland","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"2026073101224477400_cit172","doi-asserted-by":"publisher","DOI":"10.1038\/s44303-025-00127-6","article-title":"Practical\nconsiderations for clinical translation of PET imaging of adoptive\ncell therapies","volume":"3","author":"Volpe","year":"2025","journal-title":"npj Imaging"},{"issue":"3","key":"2026073101224477400_cit173","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s00259-024-07020-1","article-title":"Identifying and navigating bottlenecks\nin the translation\nof novel radiopharmaceuticals: a perspective","volume":"52","author":"Schottelius","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"2026073101224477400_cit174","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-022-00168-x","article-title":"Practical considerations\nfor navigating the regulatory landscape of non-clinical studies for\nclinical translation of radiopharmaceuticals","volume":"7","author":"Korde","year":"2022","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"1","key":"2026073101224477400_cit175","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and\nPD-L1 positron emission tomography in patients with non-small-cell\nlung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat. Commun."},{"issue":"6","key":"2026073101224477400_cit176","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI\nPET\/CT: Tracer Uptake in 28 Different Kinds of Cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026073101224477400_cit177","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2967\/jnumed.124.269002","article-title":"SNMMI\nProcedure Standard\/EANM Practice Guideline for Fibroblast Activation\nProtein (FAP) PET","volume":"66","author":"Hope","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"5","key":"2026073101224477400_cit178","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100796","article-title":"Targeting\nDLL3: A New Weapon in Lung\nNeuroendocrine Tumors?","volume":"6","author":"Riudavets","year":"2025","journal-title":"JTO Clin. Res. Rep."},{"key":"2026073101224477400_cit179","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.semcancer.2019.06.017","article-title":"Engineered nanoparticles\nfor imaging and drug delivery in colorectal cancer","volume":"69","author":"Pavitra","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"9","key":"2026073101224477400_cit180","doi-asserted-by":"publisher","DOI":"10.3390\/ph14090884","article-title":"Research and Clinical Landscape of\nBispecific Antibodies for the Treatment of Solid Malignancies","volume":"14","author":"Antonarelli","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"14","key":"2026073101224477400_cit181","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28145318","article-title":"Propagation Capacity of Phage Display Peptide Libraries Is Affected\nby the Length and Conformation of Displayed Peptide","volume":"28","author":"Kamstrup Sell","year":"2023","journal-title":"Molecules"},{"issue":"30","key":"2026073101224477400_cit182","doi-asserted-by":"publisher","first-page":"11847","DOI":"10.1039\/D4SC03207A","article-title":"A facile strategy for the construction of a phage display cyclic\npeptide library for the selection of functional macrocycles","volume":"15","author":"Xiang","year":"2024","journal-title":"Chem. Sci."},{"issue":"8","key":"2026073101224477400_cit183","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2967\/jnumed.122.265383","article-title":"Clinical\nEvaluation of 68Ga-FAPI-RGD for\nImaging of Fibroblast Activation Protein and Integrin \u03b1v\u03b23 in Various Cancer Types","volume":"64","author":"Zhao","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"10","key":"2026073101224477400_cit184","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.2967\/jnumed.123.265664","article-title":"68Ga-SSO-120\nPET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center\nRetrospective Study","volume":"64","author":"Kersting","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"2","key":"2026073101224477400_cit185","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and\nClinical Outcomes in\nMetastatic Castration-resistant Prostate Cancer Following (177)Lu-PSMA-617\n(VISION Trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"issue":"4","key":"2026073101224477400_cit186","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","article-title":"Evaluation of the SSTR2-targeted\nRadiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial\nMeningioma","volume":"30","author":"Kurz","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"2026073101224477400_cit187","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2967\/jnumed.116.176636","article-title":"68Ga\/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist\nfor Theranostic\nUse in Oncology","volume":"58","author":"Dalm","year":"2017","journal-title":"J. Nucl. Med."}],"container-title":["Chemical &amp; Biomedical\nImaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/cbmi.5c00289","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/cbihbp\/article-pdf\/4\/7\/1293\/66282625\/cbmi.5c00289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/cbihbp\/article-pdf\/4\/7\/1293\/66282625\/cbmi.5c00289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:22:49Z","timestamp":1785475369000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/cbihbp\/article\/4\/7\/1293\/5234136\/Specific-PET-Imaging-for-Precision-Management-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":187,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,2,13]]},"published-print":{"date-parts":[[2026,7,27]]}},"URL":"https:\/\/doi.org\/10.1021\/cbmi.5c00289","relation":{},"ISSN":["2832-3637"],"issn-type":[{"value":"2832-3637","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]}}}